Methylation of septin 9 (SEPT9) in tumor-derived cell-free DNA (cfDNA) is the only blood-based FDA-approved methylation biomarker for detecting CRC [22,23]. This evidence concerns the gene SEPTIN9 and colorectal carcinoma.